Why this new drug should be known in the dental practice

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Trelegy Ellipta for the maintenance treatment of asthma in patients aged 18 years and older. This new indication, and resulting increased market demand, for Trelegy Ellipta is of importance to dentistry since its ingredients have dental implications and adverse effects which, due to the fixed combination in this one product, may be additive and synergistic. Tom Viola, RPh, joins the show to discuss.

Leave a Comment